Home/Filings/4/0001493152-21-030331
4//SEC Filing

Glynn Craig 4

Accession 0001493152-21-030331

CIK 0001661053other

Filed

Dec 1, 7:00 PM ET

Accepted

Dec 2, 6:25 PM ET

Size

7.4 KB

Accession

0001493152-21-030331

Insider Transaction Report

Form 4
Period: 2021-11-30
Glynn Craig
Chief Financial Officer
Transactions
  • Award

    Stock Options

    2021-11-30+125,925125,925 total
    Exercise: $6.70Exp: 2031-11-30Common Stock (125,925 underlying)
  • Award

    Common Stock

    2021-11-30+50,00050,000 total
Footnotes (2)
  • [F1]The Reporting Person was granted 50,000 restricted stock units on November 30, 2021 pursuant to the issuer's Amended and Restated 2016 Omnibus Incentive Plan, as amended (the "Plan"). The restricted stock units are subject to milestone-based vesting as follows: (i) 50% upon SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) endpoints being achieved, and (ii) 50% upon the Pre-Market Approval of the VenoValve.
  • [F2]The common stock options were issued to the Reporting Person on November 30, 2021 pursuant to the Plan. The award is subject to time-based vesting and will vest in equal quarterly installments on the last day of each fiscal quarter during the three calendar years through 2024.

Documents

1 file

Issuer

enVVeno Medical Corp

CIK 0001661053

Entity typeother

Related Parties

1
  • filerCIK 0001809590

Filing Metadata

Form type
4
Filed
Dec 1, 7:00 PM ET
Accepted
Dec 2, 6:25 PM ET
Size
7.4 KB